Publications by authors named "L Laera"

Carnitine O-acetyltransferase (CRAT) is a crucial enzyme involved in mitochondrial energy metabolism. Alterations in CRAT activity have emerged as significant contributors to the pathogenesis of Leigh syndrome and related mitochondrial disorders. In this study we employed an integrated approach combining in silico docking analysis and virtual screening of chemical libraries with subsequent in vitro validation to identify small molecule modulators of the activity of the wild type (WT) CRAT and the p.

View Article and Find Full Text PDF

The gene () is involved in telomere maintenance and stability and plays a crucial role in the preservation of genomic stability. is considered a high-penetrance melanoma susceptibility gene; however, the number of cancer types associated with the pathogenic germline variants of is gradually increasing, including chronic lymphocytic leukemia (CLL), angiosarcomas, and gliomas, even though many associations are still elusive. Here, we reported a case of a 60-year-old man who showed early-onset multiple neoplasms, including multiple melanomas, gastrointestinal stromal tumor (GIST), and lung adenocarcinoma.

View Article and Find Full Text PDF
Article Synopsis
  • Recurrent gynecological tumors like endometrial and ovarian cancers lack effective treatments, prompting research into the PTEN-AKT-PI3K pathway as a target, with alpelisib being a notable PI3K inhibitor.
  • A study involving 36 patients with PIK3CA-mutated advanced gynecological cancers showed an overall objective response rate (ORR) of 28% and a disease control rate (DCR) of 61%, with the best results in endometrial cancer patients.
  • The findings suggest that alpelisib could be a promising treatment option for these patients and highlight the importance of further clinical trials focusing on biomarker-driven approaches for PI3K inhibitors in gynecological cancers
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the safety and effectiveness of reirradiation (re-RT) using radiosurgery or fractionated stereotactic radiotherapy in combination with regorafenib for patients with recurrent glioblastoma (GBM).
  • A total of 21 patients were observed, showing a median overall survival of 8.4 months and median progression-free survival of 6 months after treatment, with manageable side effects reported.
  • The findings suggest that this treatment approach is safe, but further prospective trials are needed to establish standard protocols.
View Article and Find Full Text PDF
Article Synopsis
  • Immune-related liver injury (irLI) occurs more frequently in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) compared to those with other solid tumors, showing an incidence of 11.4% versus 2.6%.
  • Patients with HCC experienced irLI earlier (median of 1.4 months) than those with other cancers (median of 4.7 months), but had higher rates of irLI resolution (72.1% vs. 58.3%).
  • The study suggests that while irLI leads to improved overall survival in HCC patients with milder cases, it also results in lower need for corticosteroids, indicating a different response pattern compared to
View Article and Find Full Text PDF